← All Prokidney CORP filings

Prokidney CORP 8-K filings

NASDAQ
PROK
Prokidney CORP
8-K: ProKidney Corp. Grants Supplemental Equity Awards to Retain Key Employees
ProKidney Corp. has approved supplemental equity awards, including a stock option for the Chief Legal Officer, to incentivize and retain employees.
NASDAQ
PROK
Prokidney CORP
8-K: ProKidney Corp. Updates Investor Presentation, Highlights Positive Phase 2 Data for REACT Therapy
ProKidney Corp. has released an updated investor presentation, showcasing promising Phase 2 results for their REACT cell therapy in preserving kidney function for diabetic patients at high risk of kidney failure.
NASDAQ
PROK
Prokidney CORP
8-K: ProKidney Corp. Announces $100 Million At-the-Market Offering
ProKidney Corp. has entered into an agreement with Jefferies LLC to sell up to $100 million of its Class A ordinary shares through an at-the-market offering.